GSK Appoints Omongiade Ehighebolo As Communications, Govt Affairs Director
GlaxoSmithKline, a science-led global healthcare company, has announced the appointment of Omongiade Ehighebolo as its new Communications and Government Affairs Director, Pharmaceuticals for West and Central Africa.
The company in a release to the media said, Omongiade, who joined the business in February 2017, will be responsible for strengthening and executing GSK Pharmaceutical’s overall strategic communications and government relations plans.
“He will use his deep understanding of the environment to enhance the company’s external stakeholder engagement portfolio with the aim of strengthening the healthcare infrastructure in Nigeria,” it stated.
Ehighebolo joins GSK Pharma. from Procter & Gamble, where he worked in different capacities since 2005. He brings a wealth of valuable experience spanning Communications and Government Affairs, Regulatory and Manufacturing Systems in Nigeria and across Sub-Sahara Africa.
His last role saw him responsible for Regional Regulatory, Communications and Government Relations for Procter and Gamble (P&G) Greater West Africa Operations.
A graduate of Mechanical Engineering from the University of Benin, Omon brings vast knowledge and experience to the Pharmaceutical business in Nigeria and is considered an asset to the GSK Pharmaceuticals Leadership team.
GlaxoSmithKline Consumer Nigeria (GSK Nigeria) plans to conclude arrangements in the ongoing sale of its drink business this month, according to the schedule for the N22.6b deal.
It would be recalled that in 2016, the company divest its drink business to Suntory Beverage & Food Nigeria Limited in a deal worth N22.6 billion. GSK Nigeria’s drinks business included the two iconic brands, Lucozade and Ribena.
The sale included the company’s manufacturing, bottling, marketing, distributing and selling of the Ribena and Lucozade brands in Nigeria and all assets attached to or deployed in connection with the business.
The company said, the divestment would enable the company to focus on consumer health services and ensure it continues to deliver more effective and high quality treatments for healthcare consumers.
